EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Mushroom Sources: 8

Reishi Ganoderma lucidum (Curtis) P. Karst.

Also called: lingzhi, ling zhi, Ganoderma lingzhi, Ganoderma sichuanense, mushroom of immortality

Reishi (lingzhi) is a woody polypore fungus long used in East Asian traditional medicine. Supplements are made from the fruiting body, mycelium or spore powder and sold as capsules, tablets, extracts, powders and teas.

Category
Mushroom
Forms
Fruiting body, mycelium or spore powder
Strongest evidence
C Limited
Reviewed
2026-10-28

Class 1 Well studied in people. A 2025 meta-analysis (Food Sci Nutr) pooled 17 trials (971 participants) it calls RCTs; by its study table, 10 tested G. lucidum alone (extracts or purified polysaccharide fractions) versus placebo, 7 of them marked randomized, one more had a G. lucidum-alone arm, and 6 tested multi-ingredient formulas. [8]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied3 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Reishi does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Reishi, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Blood sugar, lipids and blood pressure in type 2 diabetesCCochrane 2015: 5 trials (398 participants). In pooled data from type 2 diabetes trials (1.4–3 g/day, 12–16 weeks), HbA1c, cholesterol, blood pressure and triglycerides did not differ from placebo; risk of bias was unclear in 4 of 5 trials. [3]
Tumor response, immune measures and quality of life in people with cancerCCochrane 2016: 5 RCTs of generally poor quality. Reishi added to chemo- or radiotherapy was associated with more tumor responses (RR 1.50, 95% CI 0.90 to 2.51, though the review reports P = 0.02) and small immune-marker changes; no trial measured long-term survival. [4]
Lower urinary tract symptoms in menCOne dose-ranging RCT in 50 men aged 50 and older: an extract (0.6, 6 or 60 mg once daily) improved symptom scores (IPSS) versus placebo; urine flow, prostate volume and PSA did not change. [5]
Colorectal adenomas (precancerous polyps)CJapanese study: 123 people took a mycelial culture extract (MAK) 1.5 g/day for 12 months; adenoma number and size decreased versus 102 untreated controls selected from the same department. [2]

Main constituents: Beta-glucan polysaccharides and triterpenes [1]; Oxidized lanostane triterpenes, a complex mixture unique to the genus Ganoderma [2]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Trials in the Cochrane cardiovascular review used 1.4 g to 3 g per day for 12 to 16 weeks. [3]
  • LiverTox lists a usual dose of 500 mg to 3 grams daily. [6]
  • An open-label lung cancer study used a commercial Ganoderma polysaccharide fraction 1,800 mg three times daily for 12 weeks; group immune measures did not change. [2]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Score D
    A: well known causeE: unlikely cause

    LiverTox likelihood score D (possible rare cause of clinically apparent liver injury) (chapter last updated October 5, 2024).

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    4 listed

    Anticoagulants and antiplatelet drugs; Immunosuppressants; Chemotherapeutic agents that rely on free radicals; Cytochrome P450 substrates

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    15 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • LiverTox likelihood score D (possible rare cause of clinically apparent liver injury): a small number of cases, typically 1 to 2 months after starting, hepatocellular, usually resolving within 1 to 3 months of stopping. Many cases were poorly documented. [6]
  • A 47-year-old woman who switched from boiled reishi slices to powder developed fulminant hepatitis and died (Thailand, 2007). [6]
  • Reported side effects include nausea, insomnia, dry mouth, constipation, itching and vertigo. Case reports include hypereosinophilia with liver nodules, pseudoparasitosis, and acute neurotoxicity in a child taking several fungal supplements. [1]
  • Because of immunostimulatory effects, reishi may trigger or worsen autoimmune skin disease, although causation has not been determined. [1]
  • In the Cochrane cardiovascular review, adverse events were more frequent with reishi (RR 1.67, 95% CI 0.86 to 3.24) but were not serious. [3]
Interactions

Interactions

Reishi
From the table below 4 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Reishi
WithWhat happens
Anticoagulants and antiplatelet drugsReishi can increase the risk of bleeding; extracts may prolong INR, PT and APTT. [1]
ImmunosuppressantsReishi can enhance immune response. [1]
Cytochrome P450 substratesIn vitro, reishi polysaccharides inhibited CYP2E1, CYP1A2 and CYP3A; clinical relevance is not known. [1]
Tumor marker test CA72-4Reishi spore powder elevated serum CA72-4, which may confuse cancer monitoring. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Naming is unsettled: the European species G. lucidum and the East Asian medicinal species are not identical, and the newly accepted name for the East Asian species is G. sichuanense. Most research is still published as G. lucidum. [2]
  • Index Fungorum lists Ganoderma lingzhi as a synonym of Ganoderma sichuanense. [7]
  • Products from mycelium grown on grain contain large amounts of alpha-glucans from the grain substrate, whereas fruiting-body extracts are beta-glucan. [2]
Regulation

Regulatory status

  • US: medicinal mushrooms are sold as dietary supplements, which do not require FDA premarket evaluation and approval. The FDA has not approved medicinal mushrooms as a treatment for cancer or any other medical condition. [2]
  • China: the Chinese Pharmacopeia lists Ganoderma lucidum and Ganoderma sinense as the official species. [2]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Polysaccharides and triterpenoids, described as the most characteristic ingredients; the component(s) responsible for purported effects are unknown Polysaccharides; Terpenoids (triterpenes) [P5]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 15 entries naming Ganoderma lucidum (earliest NDI 38 submitted 1998-09-22; most recent NDI 1429 submitted 2025-07-31). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. Three further entries name an immunomodulatory protein from a different species, Ganoderma microsporum. [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC carcinogenicity evaluation of reishi (Ganoderma lucidum) was found (IARC Monographs list of classifications checked 2026-10-29). [P2]
  • No NTP carcinogenicity technical report on reishi (Ganoderma lucidum) was found (NTP technical reports list checked 2026-10-29). [P3]

Liver (NIH LiverTox)

  • LiverTox likelihood score D (possible rare cause of clinically apparent liver injury) (chapter last updated October 5, 2024). [P5]

Interactions with medicines

  • Anticoagulants and antiplatelet drugs: Reishi can increase the risk of bleeding. [P6]
  • Immunosuppressants: Reishi can enhance immune response. [P6]
  • Chemotherapeutic agents that rely on free radicals: Reishi can increase plasma antioxidant capacity and in theory may interact with these agents. [P6]
  • Cytochrome P450 substrates: In vitro, reishi polysaccharides inhibited CYP2E1, CYP1A2 and CYP3A; clinical relevance is not known. [P6]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • NCI: supplement ingredients may vary considerably from lot to lot, and there is no guarantee that ingredients claimed on product labels are present. [P7]
  • A 2020 DNA-barcoding study (nuclear ribosomal ITS region) of seven supplements sold as G. lucidum from independent suppliers identified Ganoderma lingzhi DNA in all seven; two authors were affiliated with a supplement company included in the sampling. [P8]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of each dietary-ingredient component — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants a petition-based exemption under 111.75(a)(1)(ii). [P4]
  • Species identity by DNA barcoding of the ITS region — Gunnels et al. 2020 report ITS-based phylogenetic analysis as a successful, cost-effective method for authenticating Ganoderma in supplements that are otherwise difficult to identify. [P8]
  • Alpha-glucan versus beta-glucan content (mycelium products) — NCI: mycelium grown on grain contains large amounts of alpha-glucans derived from the substrate, whereas fruiting-body extracts are entirely beta-glucan. [P7]

Supply and conservation

  • LiverTox: because it is rare in the wild, lingzhi is cultivated using logs, sawdust or wood chips from deciduous trees. [P5]
  • NCI: the European species G. lucidum and the East Asian medicinal species are not identical; the newly accepted name for the East Asian species is Ganoderma sichuanense, although most research is published as G. lucidum. [P7]

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. IARC Monographs. List of Classifications (list last updated 2026-07-23 per page data; checked 2026-10-29), 2026-07-23. monographs.iarc.who.int
  3. National Toxicology Program (NIEHS). Technical Reports list (checked 2026-10-29), 2026-10-29. ntp.niehs.nih.gov
  4. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  5. NIH LiverTox. Lingzhi, Reishi (Last Update: October 5, 2024), 2024-10-05. ncbi.nlm.nih.gov
  6. Memorial Sloan Kettering Cancer Center. About Herbs: Reishi Mushroom (Last Updated May 5, 2026), 2026-05-05. mskcc.org
  7. National Cancer Institute. Medicinal Mushrooms (PDQ)-Health Professional Version (latest update 11/06/2024), 2024-11-06. cancer.gov
  8. Gunnels T, et al. The ITS region provides a reliable DNA barcode for identifying reishi/lingzhi (Ganoderma) from herbal supplements. PLoS One 2020;15(11):e0236774 (PMID 33180770), 2020-11-12. pubmed.ncbi.nlm.nih.gov
Sources

Sources

  1. Memorial Sloan Kettering Cancer Center. About Herbs: Reishi Mushroom (last updated May 5, 2026), 2026-05-05. mskcc.org
  2. National Cancer Institute. Medicinal Mushrooms (PDQ®)–Health Professional Version (latest update 11/06/2024), 2024-11-06. cancer.gov
  3. Klupp NL, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev 2015;(2):CD007259, 2015-02-17. pubmed.ncbi.nlm.nih.gov
  4. Jin X, et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev 2016;4:CD007731, 2016-04-05. pubmed.ncbi.nlm.nih.gov
  5. Noguchi M, et al. Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study. Asian J Androl 2008;10(4):651-8, 2008-07. pubmed.ncbi.nlm.nih.gov
  6. NIH LiverTox. Lingzhi, Reishi (last update October 5, 2024), 2024-10-05. ncbi.nlm.nih.gov
  7. Index Fungorum. Ganoderma lingzhi Sheng H. Wu, Y. Cao & Y.C. Dai, record 564240 (accessed October 28, 2026). indexfungorum.org
  8. Jafari A, et al. The nutritional significance of Ganoderma lucidum on human health: a GRADE-assessed systematic review and meta-analysis of clinical trials. Food Sci Nutr 2025;13(6):e70423 (PMID 40510787), 2025-06-12. pubmed.ncbi.nlm.nih.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in mushroom: Chaga · Cordyceps · Lion's mane · Maitake · Shiitake · Turkey tail · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.